Zotepine and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Zotepine
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Taking buprenorphine (an opioid used for pain or opioid use disorder) together with zotepine (an antipsychotic) can add up in two important ways. Both can slow your breathing and make you very sleepy, and both can affect your heart's rhythm (a change called QT prolongation). Combined, that raises the risk of very deep sedation, dangerously slow breathing, and, rarely, serious heart rhythm problems.
Please don't stop either medicine on your own. This is something your care team can manage by choosing the safest combination, using the lowest doses that work, and watching you more closely. Talk with your doctor or pharmacist so they can review your plan.
Effect: Additive QT prolongation plus additive CNS and respiratory depression when buprenorphine is combined with zotepine.
- Mechanism: Pharmacodynamic additivity. Both agents prolong the QT interval; buprenorphine (opioid) and zotepine (sedating antipsychotic) each cause CNS/respiratory depression. Not a prodrug/metabolic interaction.
- Severity/Evidence: Major; probable. Onset unspecified.
- Management: Avoid combining QT-prolonging agents with buprenorphine where possible. If coadministration is necessary, use lowest effective doses, monitor sedation and respiratory status, and obtain ECG/electrolyte monitoring. Consider alternative antipsychotic options and strongly consider prescribing naloxone. Do not withhold MAT.
What happens
An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression
Interaction Deep Dive
Buprenorphine should not be given together with agents that can prolong the QT interval. Combining these medications also heightens the likelihood of respiratory depression, profound sedation, coma, and death. Discontinuing benzodiazepines or other CNS depressants is favored rather than using them concurrently. For certain patients, a taper or observation within a higher level of care may be suitable. For others, it may be suitable to slowly wean the patient off a prescribed benzodiazepine or other CNS depressant, or to reduce the dose to the lowest amount that remains effective. When concurrent use cannot be avoided, exercise careful monitoring and management; think about alternative therapies for anxiety or insomnia, and give strong consideration to prescribing naloxone for emergency treatment of opioid overdose2. A Swedish epidemiological investigation found that patients on methadone- or buprenorphine-based medication-assisted treatment (MAT) who also took benzodiazepines or other CNS depressants (for instance, medications used for insomnia) faced a greater risk of death. An analysis of pooled nationwide death certificate records spanning 2010 to 2014 showed that concomitant CNS depressant use was present in most overdose deaths that involved buprenorphine and methadone. Whether the overdose death risk from concurrent CNS depressant drugs varied between buprenorphine and methadone is not known 3.
Why it happens (mechanism)
Additive QT interval prolongation; additive CNS depression
How to manage this interaction
Both drugs can deepen sedation, slow breathing, and affect heart rhythm, so your care team manages this carefully rather than automatically stopping either one.
- Keep taking both as prescribed unless your prescriber tells you otherwise, especially if buprenorphine is treating opioid use disorder.
- Your team may use the lowest effective doses, monitor you more closely (including your heart rhythm and breathing), or consider an alternative medicine for the condition zotepine treats.
- Your prescriber may also offer naloxone for emergency use.
- Get urgent help for severe drowsiness, very slow or shallow breathing, fainting, or palpitations. Ask your pharmacist or doctor to review this combination.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A Swedish epidemiological study found that patients undergoing methadone- or buprenorphine-based medication-assisted treatment (MAT) together with benzodiazepines or other CNS depressants (for example, agents used to treat insomnia) have an increased risk of death. From July 1, 2005 to December 31, 2012, investigators compared the risk of fatal overdose, non-overdose related mortality, and all-cause mortality during periods when CNS depressants were prescribed versus periods without CNS depressant therapy in MAT-prescribed patients (aged 18 to 50). The findings showed a raised risk of all-cause mortality (adjusted hazard ratio (HR) 1.44; 95% CI, 0.93 to 2.23) and non-overdose related mortality (HR 1.74; 95% CI 1.00 to 3.01) with MAT plus benzodiazepine treatment; however, these data were not deemed statistically significant. Although results showed an increased risk of fatal overdose, non-overdose mortality, and all-cause mortality during periods of coadministration of MAT and non-benzodiazepines, only the data for fatal overdose and all-cause mortality were considered statistically significant; HR 2.34 (95% CI, 1.37 to 3.99) and HR 1.33 (95% CI, 1.12 to 2.45), respectively. The authors did not compare the benzodiazepine cohort with the non-benzodiazepine cohort because they did not adjust for the indication of use for the drugs 3.
b) A study of aggregate nationwide death certificate data from 2010 to 2014 reported 3495 drug overdose deaths in 2014. Methadone and other CNS depressants were often cited as contributors to these deaths. Concurrent ALPRAZolam use was reported in 18.1% of cases, followed by oxyCODONE (10.1%), cocaine (9.6%), heroin (9%), and diazePAM (6.6%). The FDA reported 322 drug overdose deaths in 2014 that involved buprenorphine. Of these 322 deaths, 32.9% involved ALPRAZolam, 17.4% involved clonazePAM, 11.2% involved diazePAM, 11.2% involved heroin, and 9.9% involved fentanyl. The absolute number of methadone-involved deaths was 10 times the number of buprenorphine-involved deaths, though confounding factors and differences in drug utilization were not taken into account. Whether the risk of overdose death with concomitant CNS depressant drugs differed between buprenorphine and methadone remains unknown 3.
c) Thorough QT studies of buprenorphine products have shown modest QT prolongation of 15 msec or less 1.
Common questions
Can I take Zotepine and Buprenorphine together?
Combining buprenorphine and zotepine adds up their sedative, breathing-slowing, and heart-rhythm (QT) effects, so use the lowest effective doses with close monitoring and never stop either drug on your own; talk with your care team. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Zotepine and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Zotepine and Buprenorphine interaction managed?
Both drugs can deepen sedation, slow breathing, and affect heart rhythm, so your care team manages this carefully rather than automatically stopping either one. Keep taking both as prescribed unless your prescriber tells you otherwise, especially if buprenorphine is treating opioid use disorder. Your team may use the lowest effective doses, monitor you more closely (including your heart rhythm and… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Zotepine or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: SUBUTEX(R) sublingual tablets, buprenorphine sublingual tablets. Indivior Inc (per FDA), North Chesterfield, VA, 2021. DailyMed
- US Food and Drug Administration (FDA): Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. US Food and Drug Administration (FDA). Silver Spring, MD. 2017.
Keep reading about Buprenorphine
Keep reading about Zotepine
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist